Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data.

Cram P, Girotra S, Matelski J, Koh M, Landon BE, Han L, Lee DS, Ko DT. Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data. Circulation. Cardiovascular quality and outcomes. 2020 Jan 20; 13(1):e006037.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Endovascular aortic aneurysm repair (EVAR), left ventricular assist device (LVAD), and transcatheter aortic valve replacement (TAVR) are expensive cardiovascular technologies with potential to benefit large numbers of patients. There are few population-based studies comparing utilization between countries. Our objective was to compare patient characteristics and utilization patterns of EVAR, LVAD, and TAVR in Ontario, Canada, and New York State, United States. METHODS AND RESULTS: We performed a retrospective cohort study using administrative data to identify all adults who received EVAR, LVAD, or TAVR in Ontario and New York between 2012 and 2015. We compared socio-demographics of EVAR, LVAD, and TAVR recipients in Ontario and New York. We compared standardized utilization rates between jurisdictions for each procedure. We identified 3295 EVAR recipients from Ontario and 6236 from New York (mean age 74.6 versus 74.5 years; = 0.61): 136 LVAD recipients from Ontario and 686 from New York (age, 57.4 versus 57.7 years; = 0.80): 1708 TAVR recipients from Ontario and 4838 from New York (age, 83.1 versus 83.1; = 1.0). A significantly smaller percentage of EVAR and TAVR recipients in Ontario were female compared to New York (EVAR, 15.8% versus 22.1% female; < 0.001; TAVR, 45.9% versus 51.8%; < 0.001), but for LVAD the percentage female was similar (21.3% versus 20.8%; = 0.99). Utilization was significantly higher in New York for all procedures: EVAR (12.8 procedures per-100 000 adults per-year in Ontario, 20.2 in New York; < 0.001); LVAD (0.3 in Ontario versus 1.3 in New York; < 0.001); and TAVR (6.6 in Ontario, 14.3 in New York; < 0.001). Higher utilization of EVAR and TAVR in New York relative to Ontario increased substantially with increasing age. CONCLUSIONS: We observed significantly higher utilization of EVAR, LVAD, and TAVR in New York compared to Ontario. Our results highlight important differences in how 2 different countries are using advanced cardiovascular therapies.